Cem Akin MD, PhD
Kenneth P Mathews M.D. Legacy Professor of Allergy and Immunology
Clinical Professor of Internal Medicine, Medical School
Available to mentor
Cem Akin MD, PhD
Clinical Professor
Manage Your Profile
Center Memberships
-
Center MemberAI and Digital Health Innovation
Recent Publications
-
Valent P, Hartmann K, Stefanzl G, Filik Y, Bauer K, Degenfeld-Schonburg L, Gleixner KV, Siebenhaar F, Niedoszytko M, Sperr WR, Aghaallaei N, Hoermann G, Sabato V, Orfao A, Arock M, Akin C. Current Allergy and Asthma Reports, 2026 Dec 1; 26 (1):Journal ArticleSystemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation
DOI:10.1007/s11882-026-01257-6 PMID: 41701410 -
Giavina-Bianchi P, Giavina-Bianchi M, Morais-Almeida M, Álvarez-Twose I, Bernstein JA, Broesby-Olsen S, Castells M, Gulen T, Hartmann K, Orfao A, Pongdee T, Rama TA, Siebenhaar F, Varricchi G, Martin BL, Fiocchi A, Wong GWK, Ansotegui IJ, Akin C. World Allergy Organization Journal, 2026 Oct 1; 19 (10):Journal ArticleMast cell activation syndrome: Global perspectives from a World Allergy Organization survey on knowledge, diagnosis, and access to care
DOI:10.1016/j.waojou.2026.101470 -
Akin C, Sabato V, Gotlib J, Panse J, Álvarez-Twose I, Radia DH, Livideanu CB, Jurcic J, Elberink HO, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Hartmann K, Broesby-Olsen S, Mattsson M, George TI, Shomali W, Giannetti M, Siebenhaar F, Lin HM, Bidollari I, Lampson B, Hong J, Doyle A, Tashi T, Castells M. Journal of Allergy and Clinical Immunology, 2026 Aug 1; 158 (2): 421 - 431.Journal ArticleAvapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years
DOI:10.1016/j.jaci.2026.04.001 PMID: 41985569 -
Rein L, Malinowski A, Nicoloro-Santabarbara J, Jalluri R, Cable L, Bouhana K, Crow M, Exter B, Chatfield J, Martin D, Easton R, Akin C. Clinical Lymphoma Myeloma & Leukemia, 2026 Sep 1; 26: s812Journal ArticleMPN-1139: Bezuclastinib Expanded Access Program for Patients With Systemic Mastocytosis
DOI:10.1016/s2152-2650(26)02397-9 -
Bose P, Boggs NA, Rein L, Modena BD, Sabato V, Hartmann K, Akin C, George TI, Yi CA, Elberink HO, Radia D, Reiter A, Piris-Villaespesa M, Dybedal I, Panse J, Oh S, Vachhani P, Hunter AM, Castells M, Livideanu C, van Daele P, Kirshenbaum A, Alvarez-Twose I, Vaughn J, Taparia M, Cerquozzi S, Mital A, Hus M, Romano A, Fahrenholz JM, Lansigan F, Papayannidis C, Pomares-Marin H, Rondoni M, Ustun C, Herrscher R, Pilla A, Zhang J, Sun L, Shah N, Jolin H, Easton R, Sachs J, Siebenhaar F, DeAngelo DJ. Clinical Lymphoma Myeloma & Leukemia, 2026 Sep 1; 26: s820 - s821.Journal ArticleMPN-1268: Expanded Results From the Phase 2 Summit Trial: Bezuclastinib in Adults With Nonadvanced Systemic Mastocytosis
DOI:10.1016/s2152-2650(26)02411-0 -
Bose P, Boggs NA, Rein L, Modena BD, Sabato V, Hartmann K, Akin C, George TI, Yi CA, Elberink HO, Radia D, Reiter A, Piris-Villaespesa M, Dybedal I, Panse J, Oh S, Vachhani P, MHunter A, Castells M, Livideanu C, van Daele P, Kirshenbaum A, Alvarez-Twose I, Vaughn J, Taparia M, Cerquozzi S, Mital A, Hus M, Romano A, MFahrenholz J, Lansigan F, Papayannidis C, Pomares-Marin H, Rondoni M, Ustun C, Herrscher R, Pilla A, Zhang J, Sun L, Shah N, Jolin H, Easton R, Sachs J, Siebenhaar F, DeAngelo DJ. Clinical Lymphoma Myeloma & Leukemia, 2026 Sep 1; 26: s290Journal ArticlePOSTER: MPN-1268: Expanded Results From the Phase 2 Summit Trial: Bezuclastinib in Adults With Nonadvanced Systemic Mastocytosis
DOI:10.1016/s2152-2650(26)00992-4 -
Marcus JC, Akin C, Zhang J, Easton R, Lim-Watson M, Siebenhaar F, Gwaltney C, Turner R. Quality of Life Research, 2026 Aug 1; 35 (8):Journal ArticlePsychometric evaluation of the Mastocytosis Symptom Severity Daily Diary (MS2D2) in adults with nonadvanced systemic mastocytosis (NonAdvSM)
DOI:10.1007/s11136-026-04291-z PMID: 42319518 -
Siebenhaar F, Broesby-Olsen S, Castells M, George TI, Livideanu CB, Álvarez-Twose I, Panse J, Barete S, Reiter A, Dybedal I, Akin C, Van Daele P, Radia DH, Cerquozzi S, Ustun C, Sabato V, Gotlib J, Rafferty M, DeAngelo DJ, Schafhausen P, Ungerstedt J, Ogbogu PU, Florell S, Wada DA, Rets A, Lin HM, Bidollari I, Hong J, Shaheen D, Lampson B, Hartmann K. Journal of the American Academy of Dermatology, 2026 Jun 1; 94 (6): 1705 - 1713.Journal ArticleAvapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study
DOI:10.1016/j.jaad.2026.02.025 PMID: 41690487
Featured News & Stories
Health Lab
Have an MCAS diagnosis? Well, maybe not
A leading MCAS expert breaks down what mast cell activation syndrome is and how people may be getting over, and mis, diagnosed.
Health Lab
A first-of-its-kind treatment for mastocytosis
A new drug called Avapritinib achieved longterm safety approval for indolent systemic mastocytosis.